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The increasing number of multidrug-resistant microbes now emerging necessitates the identification of novel antimicrobial agents.
Plants produce a great variety of antimicrobial peptides including hundreds of small, nodule-specific cysteine-rich NCR peptides
that, in the legume Medicago truncatula, govern the differentiation of endosymbiotic nitrogen fixing bacteria and, in vitro, can
display potent antibacterial activities. In this study, the potential candidacidal activity of 19 NCR peptides was investigated. Cationic
NCR peptides having an isoelectric point above 9 were efficient in killing Candida albicans, one of the most common fungal
pathogens of humans. None of the tested NCR peptides were toxic for immortalized human epithelial cells at concentrations that
effectively killed the fungus; however, at higher concentrations, some of them inhibited the division of the cells. Furthermore, the
cationic peptides successfully inhibited C. albicans induced human epithelial cell death in an in vitro coculture model.These results
highlight the therapeutic potential of cationic NCR peptides in the treatment of candidiasis.
1. Introduction
Candida albicans is one of the most common opportunistic
human fungal pathogens. In healthy human populations, it is
a member of the normal flora of the skin, genital, and intes-
tinal mucosa. However, C. albicans as well as other Candida
species (e.g., C. parapsilosis or C. krusei) may lead to morbid-
ity and mortality in immunocompromised patients as a con-
sequence of fungal overgrowth and severe cutaneous or sys-
temic infections. Candida exhibits fungal dimorphism both
in vitro and in vivo, growing like unicellular budding yeast
or filamentous hyphae [1].The ability for a phenotypic switch
from the budding blastospore state to a filament hyphae form
is an important factor in its virulence [2].
For the treatment of invasive candidiasis, amphotericin
B-based preparations, azoles, and echinocandins are used. In
the therapy of mucocutaneous infections (e.g., vaginal infec-
tions), azoles are the dominant agents [3]. These antifungal
drugs disturb the integrity of the fungal membranes or the
fungal cell wall. Amphotericin B binds to sterols in the fun-
gal membranes leading to leakage of monovalent ions and
consequently to cytotoxicity. Antifungal triazoles inhibit fun-
gal membrane sterol biosynthesis while echinocandins block
the synthesis of (1,3)-𝛽-D-glucan, a key component of fungal
cell wall [4].
Although the efficiency of anticandidal drugs currently
used is satisfactory, there are reports that C. albicans has
developed resistance against these agents. For example, azole-
resistant strains emerged in which mutations affected the
drug target Erg11p involved in ergosterol biosynthesis [4, 5].
Similarly, resistance against amphotericin and echinocandins
is rare; however, it does occur if levels of the plasma mem-
brane ergosterol and the cell wall (1,3)-𝛽-D-glucan are
reduced by mutations in the ERG3 and GSC1 genes, respec-
tively [4]. Although the appearance of resistant strains is not a
serious problem when compared to the spread of multidrug-
resistant bacterial pathogens, the development of novel anti-
fungal agents is still desired as a precaution.
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Since the occurrence of antibiotic-resistant superbugs
resulting from the widespread use of conventional antibiotics
is emerging, numerous studies have focused on the use of
antimicrobial peptides (AMPs) as therapeutic agents [6, 7].
AMPs represent ancient host defence effector molecules that
are present in all organisms across the evolutionary spectrum.
AMPs produced by the host innate immune system have
broad-spectrum and rapid killing activities against a wide
range of microorganisms, including fungi [8]. AMPs are usu-
ally cationic and amphipathic peptides that are able to interact
with the negatively chargedmicrobial membranes.Their kill-
ing action can be based on membrane permeabilization and
cell lysis, as well as their interactionswith cytoplasmic targets.
As multiple targets likely exist, the development of resistance
against AMPs seems less probable than in the case of classical
antibiotics [9, 10].
In contrast to the relatively low numbers of AMPs in ani-
mals, plants have evolved an extreme richness of AMPs that
are often present in specific plant organs, such as the roots,
seeds, flowers, stems, and leaves. The Arabidopsis genome
contains 317 small genes coding for cysteine-rich defensin
peptides [11]. However, AMP-like peptides not only act as
defense effectors but also can function in symbiosis control-
ling the cell number and differentiation of endosymbiotic
bacteria. This has been discovered in the Medicago trunca-
tula-Sinorhizobium meliloti symbiosis, which leads to the
development of root nodules where bacteria inside the plant
cellsmature progressively to nitrogen-fixing bacteroides. Dif-
ferentiation of the bacterium partner is irreversible and gov-
erned by host AMP-like symbiotic peptides, which are tar-
geted via the secretory pathway to the endosymbiotic bacteria
[12]. The largest group with up to 500 different members is
the nodule-specific cysteine-rich (NCR) peptide family. NCR
peptides contain a relatively conserved signal peptide and
a highly diverse mature peptide composed of 30–50 amino
acids with conserved positions of four or six cysteines. Due
to the high sequence diversity, the isoelectric point (pI) of
the peptides ranges from 3.2 to 11.2. The combined action
of different NCR peptides results in the definitive loss of cell
division ability and in the development of noncultivable poly-
ploid endosymbionts with increasedmembrane permeability.
Ex planta, several cationic NCR peptides of M. truncatula
proved to be potent killer of various Gram-negative and
Gram-positive bacteria [12, 13].
In this study, we investigated whether NCR peptides with
antibacterial activity against human and plant pathogenic
bacteria exhibit anticandidal activity and, if so, whether they
are cytotoxic for human cells. The anticandidal activity of the
peptides was tested by treatment of fungal cells with synthetic
NCR peptides and in an in vitro infection system where vagi-
nal epithelial cells were cocultured with C. albicans.
2. Materials and Methods
2.1. Strains, Media, and Peptides. TheC. albicans strainsWO-
1 and Sc5314 were maintained on YPD medium (1% (w/v)
yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose, 2% (w/v)
agar; Beckton, Dickinson and Company). Hyphal growth
was induced in complete keratinocyte medium (CKM;
Life Technologies) without serum.The effect of theNCR pep-
tides on free-living fungi was investigated either in PBgluc
buffer (1mMKH
2
PO
4
, 3mMNa
2
HPO
4
× 7H
2
O, 5% glu-
cose, pH = 7.0) or in low-salt fungal medium (LSM)
composed of 5mMK
2
HPO
4
, 100 𝜇MMgSO
4
, 10 𝜇MFeCl,
0.2 𝜇MCoCl
2
, 0.2𝜇MCuSO
4
, 4 𝜇MNa
2
MoO
4
, 1 𝜇MH
3
BO
3
,
0.2 𝜇MKI, 1 𝜇MZnSO
4
, 0.2 𝜇MMnSO
4
, 2% glucose, 0.2%
asparagine, 40 𝜇g/mL methionine, 4𝜇g/mL myo-inositol,
0.4 𝜇g/mL biotin, 2 𝜇g/mL thiamine-HCl, and 0.4𝜇g/mL
pyridoxine-HCl [14].
The immortalized human vaginal epithelial cell line PK
E6/E7 [15] was cultured in serum-free CKM supplemented
with 0.005𝜇g/mL recombinant epidermal growth factor,
50 𝜇g/mL bovine pituitary extract, L-glutamine, and antibi-
otic/antimycotic solution (Life Technologies) in a CO
2
ther-
mostat at 37∘C [16]. Cells at 60–70% confluence were used in
subsequent experiments.
Mature (without the signal peptide) andN-terminally flu-
orescein isothiocyanate (FITC) labeled NCR peptides
(Table 1) were chemically synthesized (>95% purity, Proteo-
genix, France) and dissolved in MilliQ water and were
diluted in LSM or PBgluc. Biological activity of the NCR pep-
tides was tested in LSM or PBgluc.
2.2. Antifungal Assays. The antifungal activity of the NCR
peptides againstC. albicans strains and otherCandida species
was determined in vitro using 96-well flat bottom microtiter
plates (Sarstedt). Fifty microliters of dilutions from each
peptide (final concentrations in the assays ranged from 2.5
to 100 𝜇g/mL) was added to 50𝜇L of 104 cells mL−1 and 105
cells mL−1 in LSM. The plates were incubated at 30∘C and
the peptide concentrations that prevented the germination
of yeast cells were determined by microscopic analysis and
measurement of absorbance at 600 nm with a microtiter
plate reader (FLUOstar OPTIMA; BMG Labtech) after 24
and 48 hours. Minimal inhibitory concentration (MIC) was
determined as the lowest concentration of the peptide at
which there was no visible and measurable growth after 24
hours of incubation. To determine whether the antifungal
effect was fungistatic or fungicidal, 10 𝜇L from each treatment
was dropped onto solid YPD plate after 3 and 24 hours. Plates
were incubated at 30∘C for 48 hours and developing colonies
were observed.Minimal fungicidal concentration (MFC)was
defined where no fungal growth could be observed.
To investigate the effect of the peptides on the pseudohy-
phal form, its growth was induced by incubating C. albicans
cells in serum-free CKMwithout antibiotic/antimycotic solu-
tion for 3 hours at 30∘C in a 96-well plate; then the medium
was removed and NCR peptides diluted in LSM were added.
After 2 hours of treatment, the morphological changes of
fungal hyphae were investigated by microscopy.
2.3. Fluorescent and Confocal Microscopy. C. albicans WO-1
cells were labeled with 5𝜇g/mL of the FM4-64 membrane
stain (Life Technologies) and 0.5 𝜇g/mL of the DNA stain
4󸀠,6-diamidino-2-phenylindole (DAPI, Sigma) for 15minutes
after 2 hours of peptide treatment. Images were captured
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Table 1: List of NCR peptides used in this study. Length: number of amino acids; MW: molecular weight in Da; pI: isoelectronic point.
Peptide Sequence of the mature peptide Length MW pI
NCR168 YPFQECKVDADCPTVCTLPGCPDICSFPDVPTCIDNNCFCT 41 4476 3.61
NCR095 ELVCDTDDDCLKFFPDNPYPMECINSICLSLTD 33 3770 3.62
NCR051 EEDIGGHLECVEDEDCMEESCPIFSVHKCKNSGCECDEMFR 41 4684 4.14
NCR235 DTDPFAFCIKDSNCGQDLCTSPNEVPECRLLKCQCIKS 38 4223 4.53
NCR224 KDLPFNICEKDEDCLEFCAHDKVAKCMLNICFCF 34 3987 4.65
NCR001 AFERTETRMLTIPCTSDANCPKVISPCHTKCFDGFCGWYIEGSYEGP 47 5263 5.01
NCR084 FATGMPCKTDKECPNTSTHKYKCINDDCFCFYIYWPLGNSLV 42 4856 6.71
NCR169 EDIGHIKYCGIVDDCYKSKKPLFKIWKCVENVCVLWYK 38 4565 8.45
NCR055 VNDCIRIHCKDDFDCIENRLQVGCRLQREKPRCVNLVCRCLRR 43 4759 9.21
NCR035 SFLGTFISSCKRDKDCPKLYGANFRCRKGTCVPPI 35 3910 9.42
NCR192 MKNGCKHTGHCPRKMCGAKTTKCRNNKCQCVQL 33 3708 9.54
NCR137 MTLRPCLTDKDCPRMPPHNIKCRKGHCVPIGKPFK 35 4018 9.7
NCR147 IYFPVSRPCITDKDCPNMKHYKAKCRKGFCISSRVR 36 4249 9.76
NCR280 MRVLCGRDGRCPKFMCRTFL 20 2390 9.8
NCR183 ITISNSSFGRIVYWNCKTDKDCKQHRGFNFRCRSGNCIPIRR 42 4979 10.1
NCR247 RNGCIVDPRCPYQQCRRPLYCRRR 24 3009 10.15
NCR044 AFIQLSKPCISDKECSIVKNYRARCRKGYCVRRRIR 36 4318 10.32
NCR030 AFLPTSRNCITNKDCRQVRNYIARCRKGQCLQSPVR 36 4197 10.37
NCR335 RLNTTFRPLNFKMLRFWGQNRNIMKHRGQKVHFSLILSDCKTNKDCPKLRRANVRCRKSYCVPI 64 7736 11.22
with an Axio Observer Z.1 (Zeiss) fluorescent microscope.
For studying the interaction of peptides with the fungus,
an overnight C. albicans WO-1 culture was diluted in LSM
and treated with FITC-conjugated peptides (at the sublethal
concentration of 5𝜇g/mL) for 3 hours at 30∘C. Cells were
then centrifuged for 4 minutes at 600 rpm and the unbound
peptides were removed by gentle pipetting of the supernatant
and cells were resuspended in LSM. The cell suspension was
dropped onto a coverslip and images were taken with an
Olympus FluoView FV1000 confocal laser-scanning micro-
scope.
2.4. Cell Permeability Assay. Cell permeability was moni-
tored by the release of the intracellularly accumulated dye
calcein. Overnight C. albicansWO-1 cells were washed twice
with and resuspended in 10mM potassium phosphate buffer
(pH = 7.0) at a concentration of 107 cells mL−1. Cells were
loaded with acetomethoxy-calcein at a final concentration of
5 𝜇M for 2 hours at room temperature. Cells were washed
three times to remove the extracellular dye and then 100 𝜇L
of the suspension was transferred to FIA black 96-well
plates. NCR peptides were then added at a concentration of
50mg/L, and the release of calcein (formed by the cells’ ester-
ases) was measured by its fluorescence in a microtiter plate
reader (FLUOstar OPTIMA) at excitation and emission
wavelengths of 485 nm and 530 nm, respectively. Calcein
efflux was calculated as previously reported [17].
2.5. Analysis of the Cytotoxic Effect of NCR Peptides on
Human Epithelial Cells
MTT Assay. PK E6/E7 vaginal epithelial cells were seeded in
the wells of a 96-well plate at a density of 1 × 104 cells per
well in a final volume of 100 𝜇L. CKM was then aspirated
and 100 𝜇L of the appropriate peptide diluted in PBgluc
was added. After 3 hours of incubation at 37∘C, the peptide
solution was removed, and the cells were let to regenerate
in CKM for 24 hours. Then 5mg/mL 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyltetrazolium bromide (MTT) was added to
each well and the plate was placed to 37∘C for 4 hours. The
amount of formazan formed by the activity of the mitochon-
drial succinate dehydrogenase of living cells wasmeasured by
using a microtiter plate reader (FLUOstar OPTIMA) at the
wavelength of 560 nm [18].
Real-Time Cell Analysis (RTCA). 7 × 104 PK E6/E7 cells per
well were seeded in 96-well E-plates (ACEA Biosciences) in
which the bottoms of the wells were covered with micro-
electrodes and the epithelial cells were allowed to attach to
the bottom of the wells for 20 hours. CKM was then aspi-
rated and the cells were treated with 100 𝜇L of the pep-
tides diluted in PBgluc. After 3 hours of incubation at
37∘C, the peptide suspension was removed and 200𝜇L of
CKM was added to the cells. Subsequent real-time mea-
surements of impedance were done with the xCELLigence
System RTCA HT Instrument (ACEA Biosciences) for 72
hours. The cell index at the beginning of the measure-
ment after treatment was considered as 100% and values
measured at 40 hours were expressed (see Supplementary
Figure 1 in Supplementary Materials available online at
http://dx.doi.org/10.1155/2014/320796).
10 𝜇g/mL of primycin, a macrolide lactone antibiotic
complex [19] that rapidly kills PK cells, was used as a control
for cytotoxicity in both assays.
2.6. The Effect of NCR Peptides on Vaginal Epithelial Cell:
C. albicans Coculture. PK E6/E7 cells were seeded in 96-
well E-plates as described above for RTCA. On the next
day, an overnight culture of C. albicans WO-1 was diluted
to OD = 1 and let to grow until OD = 1.5–2. The fungal cell
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suspension was diluted in antibiotic/antimycotic-free CKM
and was added to the human cells with a multiplicity of
infection (MOI) of 5. After 3 hours of coculture at 37∘C, CKM
medium was replaced with NCR peptides in PBgluc. After
3 hours of incubation, peptides were removed and 200 𝜇L
of fresh antibiotic/antimycotic-free CKM was added. Subse-
quent measurements were performed as described above.
2.7. Data Presentation and Statistics. MTT assays and impe-
dance measurements were performed in at least four tech-
nical parallels and two biological replicates; all the data are
presented asmean± standard deviation. Significance was cal-
culated with Newman-Keuls post hoc test using the Graph-
Pad Prism version 5 for Windows and a probability (𝑃) value
of less than 0.05 was considered significant.
3. Results
3.1. Anticandidal Activity of the NCR Peptides. Since cationic
defensin-like NCR peptides have been shown to be active
against a wide range of Gram-negative and Gram-positive
bacteria, including animal and plant pathogens, 19 NCR pep-
tides covering the isoelectric point (pI) spectrum of the pep-
tide family (Table 1) were investigated for anticandidal activ-
ity in microdilution plate assays. In serum-free RPMI1640
(GIBCO), NCR peptides did not have any anticandidal
activity (data not shown) which was not surprising as the
concentration of NaCl (>100mM) and the presence of Ca2+
and Mg2+ ions had been previously shown to inhibit their
bactericidal effect [12] and are known to block AMP activities
[20, 21]. Hence, the NCR activity tests were performed in
LSM medium that had been previously used successfully
to measure antifungal activity of defensins. Likewise, the
defensins [22], only cationic NCR peptides, particularly with
pI > 9.5 (NCR192, NCR137, NCR147, NCR280, NCR183,
NCR247, NCR044, NCR030, and NCR335) exhibited anti-
candidal activity against the yeast form of growingC. albicans
strains WO-1 and Sc 5314 (Table 2). The MIC values of
these peptides (Table 2) ranged from 10 to 50 𝜇g/mL (1.42–
10.5 𝜇M), which is comparable to the values observed for
amphotericin B (1.69 𝜇M).These cationic NCR peptides were
also active against other Candida species, such as C. glabrata,
C. parapsilosis, or C. krusei, at the same concentration range
as for C. albicans (10 to 50 𝜇g/mL).
In order to determine whether the cationic peptides are
fungistatic or fungicidal, C. albicans cell suspensions were
treated for 3 and 24 hours with different concentrations of
the peptides, and 10 𝜇L of the cultures was then incubated on
solid YPDmedium for 48 hrs. Anionic NCR peptides had no
effect on fungal growth. In contrast, cationic NCR peptides
exhibited rapid fungicidal activity in vitro. The MFC values
of the nine cationic NCR peptides with pI > 9.5 ranged from
6.25 to 25𝜇g/mL (Table 3) andwere comparablewith theMIC
values obtained with the microdilution assay.
The morphological changes associated with the loss of
viability were investigated with fluorescent microscopy. In
the presence of cationic NCR peptides at a concentration of
25 𝜇g/mL, a decreased size of the treated cells was detectable
Table 2: Minimal inhibitory concentration (𝜇g/mL) of the NCR
peptides against C. albicans strains WO-1 and Sc5314 after 24 hours
of treatment in vitro.
Peptide WO-1 Sc5314
NCR168 — —
NCR095 — —
NCR051 — —
NCR235 — —
NCR224 — —
NCR001 — —
NCR084 — —
NCR169 — —
NCR055 50 (±4) 50 (±3)
NCR035 — —
NCR192 10 (±2) 12.5 (±1)
NCR137 20 (±2) 25 (±2)
NCR147 19 (±9) 12.5 (±2)
NCR280 19 (±6) 25 (±3)
NCR183 19 (±6) 12.5 (±1.5)
NCR247 14 (±9) 25 (±2)
NCR044 11 (±3) 12.5 (±1)
NCR030 15 (±7) 25 (±5)
NCR335 11 (±1) 12.5 (±2.5)
—: no growth inhibition was observed.
Table 3: Minimal fungicidal concentration (𝜇g/mL) of the active
NCR peptides against C. albicans WO-1 after 3 or 24 hours of
treatments.
Peptide 3 h 24 h
NCR192 8 (±3,5) 9 (±4)
NCR137 20 (±2.5) 25 (±3)
NCR147 8 (±6.5) 9 (±4)
NCR280 10 (±2) 8 (±3)
NCR183 16.5 (±12) 15.5 (±13)
NCR247 14 (±10) 16.5 (±13)
NCR044 11 (±2) 6.25 (±1)
NCR030 12.5 (±2) 16.5 (±5)
NCR335 7 (±1) 8 (±2)
in the growing pseudohyphae after only 2 hours of treatment
(Figures 1(c), 1(e), and 1(g)). Moreover, the noncontinuous
and highly reducedmembrane labeling by the FM4-64mem-
brane stain in these cells was indicative of severe membrane
damages (Figures 1(d), 1(f), and 1(h)).
3.2. Localization of NCR Peptides in C. albicans Cells.
Although disruption of cell membranes is considered as a
general action of cationic AMPs, they might exert other
effects by entering the target cells and inhibiting DNA, RNA,
or protein synthesis [22].Therefore, the cell penetration prop-
erties and the localization of the peptides in C. albicans cells
were also investigated. For this purpose, FITC-conjugated
NCR247 peptide was synthesized; the conjugated peptide
BioMed Research International 5
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k)
(l)
(m)
(n)
(o)
Figure 1:NCRprovokedmorphological changes and localization of fluorescently labeledNCRpeptides inC. albicans cells and pseudohyphae.
((a)–(h)) PseudohyphalC. albicansWO-1 cells were either mock treated (a), (b) or treated with NCR335 (c), (d); NCR247 (e), (f); NCR192 (g),
(h) peptides at 25 𝜇g/mL concentration for 2 hours. Differential interference contrast (DIC) ((a), (c), (e), and (g)) and fluorescent ((b), (d),
(f), and (h)) images obtained after FM4-64 (cell membrane; red) and DAPI labeling (DNA; blue). ((i)–(o)) Planktonic cells were treated with
5 𝜇g/mL of FITC-conjugated NCR035 (i), (j) or NCR247 (k)–(o) and the localization of the peptides wasmonitored with confocal microscopy
3 hours after the treatment. DIC ((i), (k), and (m)) and fluorescent images ((j), (l), and (n)); (o)merged image of (m), (n). Scale bars: (a) 20 𝜇m,
(i) 100𝜇m.
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Figure 2: Time course of calcein release from NCR-treated C. albi-
cansWO-1 cells. Calcein-loaded cells were treated with the peptides
at 50 𝜇g/mL concentration and the fluorescence of the released
calcein was measured with a microtiter plate reader (excitation
485 nm, emission 530 nm).
retained comparable anticandidal activity to the unconju-
gated form (data not shown). Similarly and as a control,
the inactive NCR035 peptide was also labeled with FITC.
C. albicans WO-1 cells were treated with the FITC-labeled
peptides and the localization of fluorescence signals was
observed with confocal microscopy. As expected, NCR035
did not show interaction with the negatively charged fungal
membranes and did not label the C. albicans cells (Figures
1(i) and 1(j)), in keeping with its lack of anticandidal activity
(Table 2). In contrast, the FITC-labeled NCR247 at sublethal
concentration (5𝜇g/mL)was primarily localized to the fungal
cell membrane, but it was also detected intracellularly (Fig-
ures 1(l), 1(n), and 1(o)).These data suggest that the fungicidal
effect of cationicNCRpeptidesmight rely onmultiple targets,
not only predominantly on the fungal plasmamembrane, but
also intracellularly.
3.3. Cationic NCR Peptides Affect C. albicans Membrane Per-
meability. Membrane localization of cationic NCR peptides
as well as aberration of the membrane staining in C. albicans
cells treated with a cationic NCR peptide indicated the
potential of membrane permeabilization. This was tested
in calcein-loaded C. albicans WO-1 cells by measuring the
release of the fluorescent dye from the Candida cells after
the addition of NCR peptides at a concentration of 50 𝜇g/mL
(Figure 2). As expected, the cationic NCR peptides (NCR335,
NCR247, and NCR192) caused significant dye efflux (43.12 ±
13.05%, 29.65 ± 12.6%, and 22.82 ± 11.16%, resp.) whereas
weak cationic (NCR169) and anionic (NCR001) peptides
provoked no calcein release. These data confirm that NCR
peptides at the MIC or higher concentrations can disrupt the
integrity of the fungal membranes.
3.4. Determination of the Cytotoxicity of NCR Peptides on
Human Cells. An antimicrobial agent cannot be a successful
candidate for subsequent use in healthcare if it exhibits toxic
activity against human cells. As a consequence, in order
to determine whether NCR peptides are cytotoxic against
human cells, two cell types, vaginal epithelial cells and kerati-
nocytes (data not shown because of the similar results)
that are the targets of Candida infections, were tested. The
cytotoxicity was measured with cell viability/proliferation
assays.TheMTTassay provides information on themetabolic
state of the cells by measuring the activity of mitochondrial
dehydrogenases via the conversion of the tetrazolium dye
MTT to formazan.TheRTCA assay provides real-time, quan-
titative information about the number of the living, attached
cells by measuring electrode impedance.
The NCR peptides had no toxicity in any of the tested
media, not even in serum-free human cell media, most prob-
ably because of their inactivation by the elevated concentra-
tions of salts and divalent cations. The LSM fungal medium
was inappropriate since human cells died rapidly in this
medium already in the absence of NCR peptides (data not
shown). In contrast, in isotonic phosphate buffered saline
containing 5% glucose (PBgluc), the human cells could sur-
vive and the NCR peptides retained their antifungal activity.
In the MTT assay, cationic NCR peptides at MICs were
nontoxic for the human cells and only high concentra-
tions (e.g., >25 𝜇g/mL NCR335; 100 𝜇g/mL NCR247; and
100 𝜇g/mL NCR192) provoked cell death, unlike primycin
used for treatments of skin infections (resulting from burns)
[23] which already at 10 𝜇g/mL concentration killed epithelial
cells with about 90% efficiency (Figure 3). Importantly, the
antifungal concentration range of cationic NCR peptides
that efficiently killed C. albicans (<25 𝜇g/mL) affected only
slightly the viability of the human cells (Figure 3(a)). On the
other hand, when the cell proliferation ability was measured
with RTCA, the surviving cells showed a highly reduced
cell proliferation at 12.5𝜇g/mL concentration and at higher
concentrations they could not maintain their proliferation
ability (Figure 3(b)). The anionic NCR001 peptide had no
negative effect on the viability and proliferation of the human
cells, while the less cationic NCR169 peptide showed toxicity
only at 100 𝜇g/mL concentration (Figure 3).
3.5. NCR Peptides Successfully Inhibit C. albicans Induced Kill-
ing of Vaginal Epithelial Cells In Vitro. Low concentrations
of cationic NCR peptides efficiently eliminated C. albicans
without affecting the viability of vaginal epithelial cells. It is
the hallmark of C. albicans that it adheres to and kills human
cells, mainly by invasive hyphal growth [24]. To test if NCR
peptides are able to prevent C. albicans induced killing of
vaginal epithelial cells, an in vitro coculture model was used
in which human cells were infected with C. albicansWO-1 at
anMOI of 5 and incubated for 3 hours to allow the formation
of filaments around the human cells before the treatment
of the cultures with the NCR peptides. After incubation of
the cells for 40 hours, the fungus induced epithelial cell
death, which could be prevented by the treatment with
the cationic peptides NCR335, NCR247, and NCR192 at
both 25 and 50 𝜇g/mL concentrations (Figure 4). The less
cationic NCR169 and the anionic NCR001 peptides could not
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Figure 3: Viability/metabolic activity (a) and proliferation ability (b) of PK E6/E7 vaginal epithelial cells after NCR treatment. (a)The amount
of formazan formed after treatment was measured by the absorbance at 560 nm. (b) The relative amount of viable, attached cells 40 hours
after treatment was measured by RTCA. The number of cells that were attached when peptides were replaced with CKM after the treatment
was considered as 100%. PBgluc: mock treatment; primycin: cytotoxic control. ∗Significant (𝑃 < 0.0001) difference between the connected
treatments. ∙The observed cell number significantly (𝑃 < 0.0001) differs from that of the PBgluc and primycin controls.
eliminateC. albicans cells; these latter twoNCRpeptides were
unable to prevent vaginal epithelial cell death.
Taken together our data suggest that cationic NCR pep-
tides can efficiently kill C. albicans at the concentrations that
are nontoxic for the human epithelial cells, making them
potential anti-Candida drug candidates for use in healthcare.
4. Discussion
The present study reveals that cationic NCR peptides with a
pI above 9, that had previously been shown to have bacte-
ricidal effect on the symbiotic rhizobia as well as Gram-
negative and Gram-positive pathogenic bacteria in vitro [12,
13], are broad-spectrum antimicrobial agents. This subgroup
of defensin-like molecules proved to be effective against all
tested Candida species including C. albicans, one of the
most common opportunistic human fungal pathogens, via
inhibition of growth; more precisely, they affected survival of
both the yeast and the filamentous forms of the fungus at a
concentration range from 1.5 to 10.5𝜇M.These values are very
similar to the MIC of amphotericin B (∼1.7 𝜇M) indicating
that, in vitro, these cationic NCR peptides are as effective as
the conventional anticandidal chemical.
It is well known that several defensins exert antimicrobial
activity against bacteria and/or fungi via the permeabilization
of target cell membranes [25]. The accumulation of fluores-
cently labeled cationic NCR247 also indicates that the nega-
tively charged Candida cell membranes are primary targets
for NCR peptides. Nevertheless, based on the presence of
intracellular fluorescence labelling, cytosolic targets cannot
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Figure 4: Effects of theNCRpeptides onPKE6/E7 vaginal epithelial
cell—C. albicans coculture. The relative amount of viable, attached
cells 40 hours after treatment was measured by RTCA as in Figure 3.
25 and 50mg/L indicate treatments of the human cells only with
peptides; C. albicans 25 𝜇g/mL and C. albicans 50𝜇g/mL show the
result from treatments of the cocultures with peptides at 25 𝜇g/mL
or 50 𝜇g/mL concentrations, respectively. ∗Significant (𝑃 < 0.0001)
difference between the connected treatments. ∙The observed cell
number significantly (𝑃 < 0.0001) differs from that of the mock
(PBgluc) and infected (C. albicans) controls.
8 BioMed Research International
be excluded either. The active cationic NCR peptides caused
severe morphological changes in the fungal cells manifested
by dramatic destruction of the cell membrane structure after
only 2 hours of treatment. This membrane damage was also
supported by the release of calcein from the NCR-treated
form. Although the majority of cationic antimicrobial pep-
tides in animals induce membrane permeabilization via elec-
trostatic interaction with plasma membrane phospholipids
[26], plant defensins can achieve the same effect through
specific interaction with high affinity binding sites on fun-
gal cells [27]. For example, RsAFP2 can interact with the
fungal membrane lipid, glucosylceramide (GlcCer), thereby
arresting the fungal growth and leading to cell death [28,
29]. The fungicidal activity of the cationic NCR peptides
on Candida glabrata, a species that is unable to synthesize
GlcCer, however, suggests that GlcCer may not be the target
of these peptides; thus, it is possible that they achieve
membrane permeabilization in the same manner as animal
defensins.
Although the chemical composition of the bacterial,
fungal, andmammalianmembranes can vary to a high extent,
their major components are the phospholipids that have a
negatively charged phosphate group in the hydrophilic head,
which is targeted by membrane-disrupting cationic pep-
tides. As a therapeutic agent should not be toxic to the
patients, the cytotoxicity of selected NCR peptides on dif-
ferent immortalized human cell lines was investigated. In
contrast to the macrolide antibiotics primycin, even the most
potent cationic peptides were not cytotoxic at concentrations
that were effective against bacteria and fungi, thus indicating
that their membrane-damaging activity might not target
mammalian phospholipids and membranes. On the other
hand, they affected the proliferation of immortalized human
cells; however, it remains to be elucidated whether both
DNA synthesis and cell division, or only the cytokinesis,
were inhibited similarly to the bacterial cells when treatment
with sublethal concentrations of cationic NCR peptides
resulted in increased (up to 16 copies) DNA content [12].
The localization and the cellular targets of the peptides are
also to be determined. These results might now open new
research directions; if the molecular mechanism of the cell
division inhibition can be revealed and the targeted delivery
of the active cationic peptides to the cancer cells, as well as the
maintenance of their activity during administration, can be
achieved, these peptides might arrest the growth of tumors.
The active cationic NCR peptides not only could elimi-
nate the yeast form of the fungi, but also were able to prevent
the growth and the subsequent human cell killing activity of
the hyphal form in an in vitro coculture model.This indicates
that, with proper formulation that helps to maintain the
activity of the peptides on the human epithelial surface, they
might be effective drugs for the treatment of candidiasis.
5. Conclusions
Most of the tested cationic NCR peptides showed both
bactericidal and fungicidal activities; thus, they may be con-
sidered as broad-spectrumAMPs. In contrast to the antibiotic
complex primycin, NCR peptides showed toxicity on the
epithelial cells at much higher concentrations than their
MFC/MIC against Candida species. The NCR peptide con-
centrations that efficiently eliminated the fungi (this work)
and bacteria [12, 13] did not affect the survival of the human
cells but did restrict their proliferation.These features qualify
the peptides to become true candidates for the treatment of
microbial infections. It must be noted, however, that salts
and components of the serum inhibit the activity of NCR
peptides similarly to other AMPs. Therefore, NCR peptides
or their derivatives could be ideal antimicrobial agents for
topical treatments while their salt and serum sensitivity may
limit their utilization as systemic compounds or require their
special delivery to the infected tissues or even to cancer cells.
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